Healthcare / Diagnostics & ResearchNasdaqGS
$4.28
+0.31 (+7.81%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-38.4M · quality 57.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$404M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-99.4%
↓Gross Margin
69.9%
↑Debt/Equity
0.57
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+6.0%
FCF CAGR
—
FCF margin
-3.1%
FCF / Net income
0.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $824.5M · net income $-365.9M · FCF $-25.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $824.5M | $824.5M | $837.6M | $753.2M | $678.4M | $690.6M | $557.1M | $851.1M | $743.7M | $728.7M | $740.5M | $722.5M | $778.2M | $613.2M | $496.0M | $402.1M | $362.6M | $326.5M |
| Net Income | $-365.9M | $-365.9M | $-127.3M | $-263.3M | $-112.0M | $-27.2M | $-223.6M | $4.6M | $133.3M | $17.4M | $117.2M | $79.8M | $176.2M | $147.2M | $112.2M | $100.7M | $152.3M | $84.6M |
| EBITDA | $-330.9M | $-330.9M | $-59.5M | $-197.4M | $-84.7M | $-127.7M | — | $80.6M | $176.3M | $92.3M | $180.2M | $158.6M | $288.2M | $236.9M | $189.4M | $165.0M | $142.2M | $135.9M |
| EPS | -3.95 | -3.95 | -1.41 | -3.18 | -1.39 | -0.35 | -2.99 | 0.06 | 1.85 | 0.25 | 1.60 | 1.07 | 2.25 | 1.77 | 1.30 | 1.10 | 1.54 | 0.86 |
| Gross Margin | 69.9% | 69.9% | 69.9% | 68.6% | 70.2% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -8.2% | -8.2% | -10.5% | -19.2% | -18.2% | -27.6% | -52.0% | 0.9% | 16.4% | 6.0% | 20.7% | 18.5% | 35.3% | 37.2% | 36.4% | 39.2% | 37.2% | 38.7% |
| Net Margin | -44.4% | -44.4% | -15.2% | -35.0% | -16.5% | -3.9% | -40.1% | 0.5% | 17.9% | 2.4% | 15.8% | 11.0% | 22.6% | 24.0% | 22.6% | 25.0% | 42.0% | 25.9% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.57 | 0.57 | 0.20 | 0.19 | 0.16 | 0.00 | 0.26 | 0.21 | 0.01 | 0.13 | — | — | — | — | — | — | — | — |
| Current Ratio | 2.67 | 2.67 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-25.6M | $-25.6M | $-38.4M | $-184.2M | $-151.6M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Returns | ||||||||||||||||||
| ROE | -99.4% | -99.4% | -18.2% | -33.6% | -12.6% | -2.8% | -25.4% | 0.4% | 13.8% | 2.3% | 15.8% | 12.1% | 24.5% | 20.2% | 17.6% | 17.8% | 27.3% | 19.5% |
| Valuation | ||||||||||||||||||
| P/B | 1.08 | 1.08 | 1.77 | 1.86 | 1.49 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | -1.6% | -1.6% | 11.2% | 11.0% | — | 24.0% | -34.5% | 14.4% | 2.1% | -1.6% | 2.5% | -7.2% | 26.9% | 23.6% | 23.4% | 10.9% | 11.1% | — |
| EPS Growth | -180.1% | -180.1% | 55.7% | -128.8% | — | 88.3% | -5083.3% | -96.8% | 640.0% | -84.4% | 49.5% | -52.4% | 27.1% | 36.2% | 18.2% | -28.6% | 79.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+2.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.41 → -3.95
Residual
+2.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.